Cumulative incidence of MR^4.5 and Stable MR^4.5 after 8 years of imatinib therapy according to various factors. (A-B) Patients were grouped according to the BCR-ABL1 value at 3 months. The asterisks indicate the P values for the difference from the next BCR-ABL1 group. (C) Cumulative incidence of Stable MR^4.5 at 5 years after achieving a confirmed MMR, for the patients who achieved MMR by 18 months (P < .001) (MMR by 6 months vs MMR by 12 months; P = .002). (D) Women had a significantly higher cumulative incidence of Stable MR^4.5 than men.